PMID- 29224320
OWN - NLM
STAT- MEDLINE
DCOM- 20190212
LR  - 20231111
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 38
IP  - 11
DP  - 2017 Nov 14
TI  - [Comparative study of cytogenetic response evaluated by conventional banding 
      analysis and fluorescence in situ hybridization in chronic myeloid leukemia 
      patients during tyrosine kinase inhibitor treatment].
PG  - 962-967
LID - 10.3760/cma.j.issn.0253-2727.2017.11.012 [doi]
AB  - Objective: To compare the cytogenetic response detected by conventional banding 
      analysis (CBA) and fluorescence in situ hybridization (FISH) and to explore the 
      correlation between the cytogenetic and molecular response in chronic myeloid 
      leukemia (CML) patients during tyrosine kinase inhibitor (TKI) treatment. 
      Methods: CBA, FISH and real-time quantitative reverse transcriptase polymerase 
      chain reaction (RQ-PCR) methods were performed to detect the cytogenetic and 
      molecular response simultaneously in 504 bone marrow samples from 367 CML 
      patients who received TKI treatment. Results: Among 504 samples, 344 were 
      detected to reach complete cytogenetic response (CCyR) by CBA, while 297 samples 
      reached CCyR by FISH which were considered to carry BCR-ABL positive cells<1%. 
      When the results of CBA, FISH and RQ-PCR were compared in 493 samples at the same 
      time, it showed that in 337 samples with CBA-CCyR, 273 (81.0%) reached FISH-CCyR 
      and 289 (85.8%) were BCR-ABL(IS) (International Scale, IS) </=1% by RQ-PCR, 
      compared to 9.0 (261/290) were BCR-ABL(IS) </=1% among 290 samples with FISH-CCyR. 
      There was no significant difference in the median value of BCR-ABL(IS) between 
      samples in CBA-CCyR and FISH-CCyR (0.21% vs 0.13%, z=-1.875, P=0.061) . 
      Furthermore, when the samples were divided into three groups according to BCR-ABL 
      positive cells (0,>0~<1%, 1%~5%) by FISH, the statistical difference was 
      observed, the proportion of samples with BCR-ABL(IS) </=1% in the three groups were 
      94.1%, 57.6% and 27.7% respectively (chi(2)=43.499, P<0.001; chi(2)=9.734, P=0.003) , 
      while the median value of BCR-ABL(IS) were 0.10%, 0.64% and 1.80% respectively 
      (z=-5.864, P<0.001; z=-4.787, P<0.001) . Conclusion: FISH results were in good 
      concordance with CBA in identify samples in CCyR, FISH was more sensitive and had 
      better correlation with RQ-PCR results than CBA, but how to define FISH-CCyR need 
      further study.
FAU - Wang, Z
AU  - Wang Z
AD  - Peking University People's Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 
      100044, China.
FAU - Li, N
AU  - Li N
FAU - Gao, L
AU  - Gao L
FAU - Feng, L
AU  - Feng L
FAU - Qin, Y Z
AU  - Qin YZ
FAU - Dang, H
AU  - Dang H
FAU - Shi, Y
AU  - Shi Y
FAU - He, Q
AU  - He Q
FAU - Jiang, Q
AU  - Jiang Q
FAU - Jiang, H
AU  - Jiang H
FAU - Lai, Y Y
AU  - Lai YY
LA  - chi
PT  - Comparative Study
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Bone Marrow
MH  - Fusion Proteins, bcr-abl
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
MH  - Protein Kinase Inhibitors/*therapeutic use
PMC - PMC7342782
OTO - NOTNLM
OT  - Cytogenetic analysis
OT  - In situ hybridization, fluorescence
OT  - Leukemia, myelogenous, chronic, BCR-ABL positive
EDAT- 2017/12/12 06:00
MHDA- 2019/02/13 06:00
PMCR- 2017/11/01
CRDT- 2017/12/12 06:00
PHST- 2017/12/12 06:00 [entrez]
PHST- 2017/12/12 06:00 [pubmed]
PHST- 2019/02/13 06:00 [medline]
PHST- 2017/11/01 00:00 [pmc-release]
AID - cjh-38-11-962 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2017.11.012 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2017 Nov 14;38(11):962-967. doi: 
      10.3760/cma.j.issn.0253-2727.2017.11.012.